Howard Wolinsky
The days of painful fingerpricks to measure blood sugar levels with glucometers finally may be over for many patients with diabetes, especially for the 1.2 million Americans with type 1 diabetes but also for at least 1.75 million patients with type 2 diabetes who control their condition by self-injecting…
Value-based agreements between insurers and drugmakers have gotten a lot of attention lately, but device makers, including those that make continuous glucose monitors, are also making deals with insurers that tie payment to how the device performs. Suzanne Winter Suzanne Winter, vice president of…
News Wire
The company announced that it plans to reduce other drugs in its portfolio as well.
Where you live will play a large part in what kind of coverage you can get. Just like the (good?) old days.
But diabetes group tamp down expectations.
An impurity has been found to be carcinogenic.
The move is considered part of the antiterrorism effort.
Richard Mark Kirkner
It is finally starting to happen. The first gene therapy to treat an inherited disease is out of the gate. But my, that price tag: $850,000. Many more gene therapies are on their way. How can they be priced to hit the sweet spot of affordability, access, and innovation? Outcomes-based pricing doesn’t really do the trick.
Value-Based Tools
Michael D. Dalzell
A report detailing clinic-level cost and quality of cancer care in Washington State is a first—adding its own stamp on efforts to measure value in oncology.
Viewpoint
Bruce Pyenson
Despite standardization, advocates for various industries and certain patient needs continue to propose changes in coverage rules. Much of the advocacy is occurring at the state level with a focus on pharmaceutical coverage, such as equalizing cost sharing between oral and infused oncology drugs or setting limits on cost sharing for prescriptions.
CURRENT ISSUE July 2018

New World of Genetic Tests and Drugs Is Coming at You

How to cope with the avalanche of information? It won’t be easy. Of the approximately 70,000 genetic tests that have emerged from clinical laboratories only a minutely small number have gained a consensus among scientists as being medically actionable, and the CDC, so far, has identified just four that have enough evidence to possibly be used to screen asymptomatic people. How can you make sure that the tests are being properly used? Could genetic counselors as standalone practitioners be part of the answer?

Then, there’s the expense of gene therapy. Thirty million Americans have a rare disease. If 12.2% are uninsured, that leaves about 26.3 million covered lives. What if 5% of them get an $850,000 treatment? The bill would be $1.227 trillion, four times the nation’s 2016 total prescription drug bill of $328.6 billion.

Mind-boggling.

UPCOMING MEETINGS
San Diego, CA
August 28-30, 2018
Las Vegas, NV
September 13-14, 2018
Las Vegas, NV
September 13-14, 2018
Las Vegas, NV
September 13-14, 2018
Washington, DC
September 27-28, 2018
Washington, DC
September 27-28, 2018
Cover Story
Jan Greene
Genetic testing has taken off and may usher in a new era of genetically tailored health care. Insurers are figuring out how to cope with the avalanche of information. Could genetic counselors as standalone practitioners be part of the answer?
Legislation & Regulation
Richard Mark Kirkner
Michael S. Sinha, MD
The FDA’s work to redefine ‘truthful and non-misleading’ communication may preempt state efforts.